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CancerClinical experience with adenovirus vectors has highlighted the need for improved delivery and targeting.
Tumour-associated endotheliumoffers an additionalmechanism for enhanced viral uptake into tumourswhich
is accessible for systemic gene delivery. Building on expertise in using polymer ‘stealthed’ viruses for targeting
in vivo, adenovirus expressing luciferase (Adluc)was coatedwith an amino-reactive polymer based on poly [N-
(2-hydroxypropyl) methacrylamide] to ablate normal infection pathways. Direct linkage of a monoclonal
antibody against E-selectin (MHES) demonstrated E-selectin-speciﬁc transduction of tumour necrosis factor-α
(TNF-α)-activated endothelial cells. A two-component targeting system using protein G was developed, to
provide optimal antibody orientation. We report an enhancement in transduction of TNF-α-activated
endothelium in vitro and ex vivo in a human umbilical vein cord model using the MHES antibody. Similarly a
virus retargeted using a chimeric P-selectin Glycoprotein Ligand-1-Fc fusion (PSGL-1) protein showed better
circulation kinetics and signiﬁcant uptake into HepG2 xenografts following systemic administration in mice,
with 36-fold higher genome copies, compared with non-modiﬁed virus. Immunohistochemistry staining of
tumour sections from mice treated with PSGL-1-retargeted virus showed a co-localisation of ﬁreﬂy luciferase
with CD31 suggesting selective endothelial targeting. Employment of optimal viral modiﬁcation using protein
G will enable exploration and comparison of alternative targeting ligands targeting tumour-associated
endothelium.at Tel.: +44 1865 617041; fax:
ax: +44 1865 617028.
.uk (H. Bachtarzi),
.seymour@clinpharm.ox.ac.uk
isher).
 license.© 2010 Elsevier B.V. Open access under CC BY license.1. Introduction
Gene therapy as a concept provides an appealing alternative to
small drugs for the treatment of complex diseases like cancer,
allowing expression of speciﬁc therapeutic proteins rather than
being limited to inhibition of tumour-associated targets. In addition,
gene therapy offers the advantages of power through ampliﬁcation of
gene products, speciﬁcity through the use of tissue-speciﬁc promoters
and, versatility, delivering agents with different mechanisms of action
such as: suicide genes (virus-directed enzyme prodrug therapy) and
immuno-modulatory proteins [1]. To date, most cancer gene therapy
approaches have targeted tumour cells by local administration
protocols, with few having evaluated targeting tumour-associated
endothelium [2,3].
Therapeutic strategies that target tumour-associated vasculature
have several advantages compared with direct targeting of tumourparenchymal cells. Firstly, the endothelium represents a primary point
of contactwith blood-bornemolecules and is easily accessible from the
bloodstream. Secondly, tumour-associated endothelium displays
many similar properties regardless of tumour type that distinguish it
fromnormal endothelium, giving rise to a broad class of therapy. Lastly,
destruction of a relatively small number of endothelial cells has the
potential to deprive many tumour cells of oxygen and nutrients,
leading to an avalanche of tumour cell death [4].
Unlike normal endothelium, tumour-associated endothelial cells
often display an inﬂamed phenotype due to activation by cytokines
emanating fromthe tumour including tumournecrosis factor-α (TNF-α)
and interferon-γ (INF-γ) [5]. This pro-inﬂammatory activationpromotes
faster endothelial proliferation and results in up-regulated levels of cell
surface markers. αvβ3 integrins, vascular endothelial growth factor
receptors and E-selectin have all been reported to be over-expressed on
tumour-associated endothelium [6,7].
Selectins are a family of structurally-related, Ca2+-dependent,
type-I transmembrane carbohydrate-binding proteins which include:
E-selectin (CD62E), P-selectin (CD62P) and L-selectin (CD62L). E-
selectin and P-selectin are of particular interest in inﬂammation and
cancer, as they are functionally used by circulating macrophages to
home towards the regions of disease [8,9]. Both E- and P-selectins are
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an endosomal pathway, and have successfully been exploited to target
tumour-associated vasculature in vivo [10,11]. Redirecting viral
tropism via endothelial selectins is therefore an attractive option
worth further study. Ogawara et al. examined redirecting adenoviral
tropism using bifunctional PEG attached to the surface of the virus
capsid inhibitingﬁbre knob/CAR interactions. Subsequent introduction
of E-selectin antibodies to functional groups of the PEG molecule
allowed retargeting to activated endothelial cells in vitro and in vivo
[12]. Despite the conceptual advantages of targeting therapeutics using
viruses to endothelium, this strategy remains fraught with difﬁculties
due to complement [13,14], antibodies [14], blood cell binding [15–17],
clotting factor interactions [18,19] and liver capture [20,21]. In an effort
to improve virus bloodstream circulation and survivability for a
sufﬁcient time to allow vascular targeting, we have used a polymer
encapsulation technique based on poly-[N-(2-hydroxypropyl) metha-
crylamide] (pHPMA) to de-target viruses and protect against unwant-
ed vector–host interactions [17]. Several ligands have previously been
successfully incorporated ranging from peptides to monoclonal
antibodies [22–24]. Onedrawbackof this approach for usingantibodies
as targeting ligands is the randomnature of antibodyorientation on the
polymer due to the presence of multiple reactive amino groups.
Krasnykh and co-workers have previously shown that genetic
modiﬁcation of the Ad ﬁbre protein incorporating the immunoglobulin
(Ig)-binding domain of Staphylococcus aureus protein A, created a
vector capable of binding targeting ligands incorporating the Fc
domain of immunoglobulin. Targeting ligands incorporating CD40
single chain antibodies or CD40Lmediated a signiﬁcant increase in the
transduction of CD40-positive target cells [25].
In order to identify receptors and ligands that may be useful for
endothelial targeting we chose to use Streptococcus aureus protein G
(StrepG) as a platform targeting system. The advantage of this approach
is that it allows a correctly orientated linkage of Fc-bearing ligands to
tropism-ablatedpolymer coatedvirus particles. Accordingly in this study
we have explored theuse of StrepG-based retargeting of polymer coated
adenovirus to endothelial selectins in vitro, ex vivo and in vivo.
2. Materials and methods
2.1. Cell lines
Human Umbilical Vein Endothelial cells (HUVECs; PromoCell,
Heidelberg, Germany) were maintained in EGMTM-2-Endothelial Cell
Medium-2 (Cambrex Bio Science, Walkersville, USA), supplemented
with hydrocortisone, h-FGF-B, VEGF, R3-IGF-1, ascorbic acid, heparin,
FBS, hEGF, andGA-1000 (Cambrex Bio Science,Walkersville, USA). Brain
endothelioma cell line (bEnd-3; ATCC, Manassas, USA) was grown in
Dulbecco'smodiﬁedEagle'smedium(DMEM) containing20 mMHEPES,
10% foetal calf serum (FCS) and 2 mM glutamine (PAA laboratories,
Yeovil, UK). HepG2 human hepatocyte carcinoma were maintained in
Minimal Essential Medium with Earle's salts (EMEM), 2 mM glutamine
(PAA Laboratories GmbH,UK), supplementedwith 10% FCS, and0.1 mM
non-essential amino-acids. The H18/7 (mouse IgG2a anti-human E-
selectin) monoclonal antibody-producing hybridoma (ATCC, Manassas,
USA) was grown in RPMI 1640 medium (PAA Laboratories, Yeovil, UK)
supplemented with 10% horse serum (Invitrogen, Paisley, UK) with
NEAA (PAA laboratories, Yeovil, UK) and 1 mM sodium pyruvate
(Sigma-Aldrich, Gillingham, UK).
2.2. Antibodies
MHES (mouse IgG2a anti-human E-selectin) monoclonal antibody
was puriﬁed from the H18/7 culture medium by protein A afﬁnity
columns (nProtein A sepharose 4 fast ﬂow, GE Healthcare). Themouse
IgG2a isotype control monoclonal antibody was kindly provided by
Prof P.E. Thorpe (University of Texas, Southwestern Medical Center,Dallas). RMES (mouse IgG2a anti-rat E-selectin) monoclonal antibody
was purchased from BD Pharmingen (Oxford, UK). Recombinant
human P-selectin Glycoprotein Ligand-1 (PSGL-1)-/IgG1 Fc fusion
protein was purchased from R&D systems (Abingdon, UK). Ad5 ﬁbre
was a gift from Dr. R. Carlisle (University of Oxford, UK).
2.3. Viruses
E1, E3-deleted Ad5 expressing cytomegalovirus immediate-early
(CMV IE) promoter-driven luciferase (Adluc)was grown inHEK293 cells
until a cytopathic effect was observed. Virus was released from cells by
freeze/thawing, extracted with N-butanol and puriﬁed by double
banding on a CsCl gradient with an intermediate benzonase (Merck
Biosciences, Nottingham, UK) step to remove contaminating DNA. The
virus was dialysed into 50 mMHEPES/phosphate-buffered saline (PBS),
10% glycerol pH 7.8 (storage buffer) and stored in small aliquots. Particle
numbers were estimated using the PicoGreen assay (Molecular Probes,
Paisley, UK) assuming 1 μg/ml DNA=2.7×1010 particles/ml [26].
Typical particle:infectivity ratios of 10:1 were obtained.
2.4. Virus modiﬁcation
2.4.1. Direct conjugation of antibody
Amino-reactive multivalent hydrophilic polymer based on poly[N-
(2-hydroxypropyl)methacrylamide] [pHPMA-gly-gly-TT] [27] supplied
by Institute ofMacromolecular Chemistry (Prague, CzechRepublic)was
resuspended inwater tomake a 100 mg/ml polymer stock solution. Ten
μl was then added to 90 μl of virus for 40 min at room temperature
(pcAdluc). Free un-reacted polymer was removed from pcAdluc using
S400 micro-spin columns (Amersham Biosciences, Buckinghamshire,
UK) according to themanufacturer's instructions.Mouse anti-human E-
selectin monoclonal antibody (MHES) was conjugated to pcAdluc by
adding 0.5 mg/ml antibody to the virus initially for 1 h at room
temperature and then overnight at 4 °C.
2.4.2. Indirect conjugation through protein G
pcAdluc was generated by incubating 1 ml of Adluc (1–3×1012 par-
ticles/ml) in storage buffer with the pHPMA-gly-gly-TT polymer at a
ﬁnal concentration of 10 mg/ml for 40 min at room temperature.
pcAdluc was puriﬁed away from the unincorporated polymer by
caesium chloride banding and subsequently mixed with S. aureus
protein G (StrepG) (Sigma-Aldrich, Gillingham, UK), at a ﬁnal
concentration of 1 mg/ml for 1 h at roomtemperature before incubation
overnight at 4 °C. Protein G-reacted polymer coated virus (StrepGpcA-
dluc) was puriﬁed again by caesium chloride banding to remove
unincorporated StrepG proteins. Mouse anti-human E-selectin mono-
clonal antibody (MHES) (10 μg/ml), rat anti-mouse E-selectin mono-
clonal antibody (RMES) (1-100 μg/ml) or chimeric P-selectin
Glycoprotein Ligand-1 (PSGL-1)-Fc fusion protein (1-50 μg/ml), were
linked via their Fc regions to StrepG-modiﬁed polymer coated virus
through afﬁnity interaction following a 1 h-incubation at room
temperature.
2.5. Dot blot analysis
The amount of protein G associated with each virus particle was
determined by dot blot analysis. A standard curve of protein G ranging
from 78 to 5000 pg was prepared by serial dilution and application to a
nitrocellulose membrane. Puriﬁed StrepGpcAdluc was serially diluted
and added to the nitrocellulose membrane (ranging from 1.5×106 to
1×108 virus particles). The nitrocellulose was then probed with
polyclonal anti-protein G antibodies (Abcam, Cambridge, UK) diluted
1:2000, followed by goat anti-rabbit-HRP antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted 1:2500. Signals were
visualised using ECLWestern blotting detection reagent (GE Healthcare
Biosciences, Chalfont St. Giles, UK).
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HUVECs were treated with PBS or 100 ng/ml rhTNF-α (R&D Systems
EuropeLtd, Abingdon,UK) for 4 hat 37 °Cand thenanalysed for E-selectin
expression. Cells were gently scraped and placed into 96 well V-bottom
plates. Cells were then incubated with 10 μg/ml MHES antibodies for
40 min at 4 °C, followed by a second incubation (40 min, 4 °C)with a goat
anti-mouse antibody, conjugated to R-Phycoerthyrin. Cells were analysed
(5×103 events counted, approximately 4×103 events gated) by ﬂow
cytometry at 585±21 nmusing a FACSCalibur (BectonDickinson,Oxford,
UK) and CellQuest Pro software (Becton Dickinson, Oxford, UK); the M1
gate was set using the mock (no antibody) control.
2.7. Transduction assays
HUVECs or bEnd3 cells were seeded into 96-well plates at 10,000
cells per well 24 h prior to infection and were incubated in triplicate
with 1000 virus particles/cell of Adluc, pcAdluc, StrepGpcAdluc or
MHES/RMES/PSGL-1-Fc-StrepGpcAdluc in 100 μl infection medium
(DMEM, 2% FCS, 2 mM glutamine). After 90 min, the infectious
medium was removed and 100 μl normal cell growth medium was
added to cells. Transgene expression was measured 24 h later using
the bright-GloTM luciferase assay system (Promega, Southampton,
UK) and a Victor 2 plate reader (Perkin Elmer) or a luminometer
(LB9507; Berthold Technologies, Bad Wildbad, Germany). Cell lysates
were assayed for protein content using the BCA assay (B9643; Sigma-
Aldrich, Gillingham, UK).
2.7.1. Competition (blocking) assay
CAR was blocked by incubating cells with 10 μl Ad5 ﬁbre. E-selectin
was blocked with 20 μg/ml MHES antibody or isotype control antibody.
Cells were blocked at 4 °C for 30 min and without removing antibodies
were then infectedat1000MOI for1 h at37 °C. Viruswas then removed,
fresh media added and transgene expression measured after 24 h.
2.8. Infection of umbilical cord ex vivo
Human umbilical cords were obtained from healthy females
courtesy of the Delivery Suite, Department of Obstetrics and Gynaecol-
ogy, John Radcliffe Hospital, Oxford. They were stored at 4 °C in sterile
PBS andusedwithin 24 h. A freshhumanumbilical cordwas rinsedwith
PBS to remove residual blood cells, cut in to small pieces (1–2 cm)with a
scalpel, incubated in EGMTM-2-Endothelial Cell Medium-2 (2% FCS) and
stimulated with or without 50 ng/ml recombinant human TNF-α
(rhTNF-α; R&D, Abingdon, UK) for 4 h at 37 °C. The sections of cord
were infected with 1×1010 Adluc or MHES-StrepGpcAdluc particles in
serum-depleted growth media. After 90 min, the infectious medium
was removed; tissues were washed with PBS and re-incubated in
complete HUVEC growth medium for 24 h.
2.8.1. Immunohistochemical staining of frozen umbilical cord sections
Twenty four hours post-virus infection, pieces of umbilical cord
were snap frozen in dry ice. Serial Cryostat 10 μm sections were cut,
air dried onto microscope polylysine slides (Thermo scientiﬁc,
Braunschweig, Germany) overnight at 37 °C, and then ﬁxed with
Cell-FixxTM (Thermo Electron Corporation, Cheshire, UK) for 4 h at
room temperature. For double-immunoﬂuorescence staining, sections
were washed in PBS and blocked with 10% heat-inactivated goat
serum (Sigma-Aldrich, Gillingham, UK) containing 0.3% Triton X-100
in PBS for 30 min at room temperature. Primary antibodies: a rabbit
anti-luciferase polyclonal and a mouse IgG1 anti-human CD31
monoclonal antibodies (abcam, Cambridge, UK) were diluted 1/
1000 and 1/10, respectively in 1% heat-inactivated goat serum
containing 0.3% Triton X-100 and incubated on sections for 45 min
at room temperature. Sections were then washed in PBS and stained
for 45 min at room temperature with a combination of two secondaryantibodies: a goat anti-rabbit-Alexa Fluor 488 (Invitrogen, UK),
diluted 1/200 in 1% goat serum to detect rabbit anti-luciferase
antibody binding and a goat anti-mouse-Alexa Fluor 594 (Invitrogen,
UK), diluted 1/200 in 1% goat serum to detect mouse anti-human
CD31 antibody binding. Slides were washed in PBS and were then
mounted in mounting media containing DAPI and kept in the dark.
2.8.2. Fluorescence microscopy
Sectionswere imaged using a confocalmicroscopeNikonOptiphot-2
upright microscope, ﬁtted with 5×, 10×, 20× and 40× objectives, a 60×
oil immersion objective and Bio-Rad MRC 1024 with Krypton/Argon
lasers, emitting a green light at 488 nm (for Alexa Fluor 488) and a red
light at 568 nm (for Alexa Fluor 568) and at 594 nm (for Alexa Fluor
594). Images were processed using LaserSharp 2000 image processing
software (Bio-rad).
2.9. In vivo studies
Female nude mice aged 4–6 weeks (Charles River Laboratories, Kent,
UK) were housed and cared for according to Home Ofﬁce regulations.
HepG2 cells (5×106) were implanted by subcutaneous injection and
animals were monitored on a regular basis until tumours were just
palpable and were adequately vascularised.
For kinetics studies, mice were anaesthetised by isoﬂuorane
inhalation and virus samples (Adluc or PSGL-1-Fc-StrepGpcAdluc)
were injected into the tail vein using a 29-gauge insulin syringe (Becton
Dickinson,Oxford,UK). Blood sampleswere taken from the tail vein at 5,
10, 20 and30 min after virus injection. A blood volume corresponding to
2.0 ml/mouse was assumed for calculation of virus present in the
bloodstream.
For retargeting studies, mice were divided into 4 groups (4 mice
each) and given clodronate liposomes (100 μl) followed 24 h later by
an intravenous injection 1×1010 virus particles of Adluc, StrepGpcA-
dluc, IgG1-StrepGpcAdluc or PSGL-1-Fc-StrepGpcAdluc. After 24 h,
the animals were culled; tumours were harvested, frozen in dry ice
and cut using a cryostat into 10 μm sections as described above.
Sections were incubated with rat anti-mouse CD31 monoclonal
antibody to stain for tumour-associated mouse vasculature and anti
luciferase antibodies as described above. CD31 was detected using
goat anti-rat-Alexa Fluor 568 secondary antibodies. Immunostained
sections were analysed by confocal microscopy as described above.
2.10. Quantitative-PCR analysis
Quantitative PCR (Q-PCR) was used to detect the presence of
adenovirus DNA in extracted DNA samples using an ABI 7000 Sequence
Detection System and software. Ampliﬁcation of an 84 bp fragment of
the adenovirus ﬁbre gene was carried out using the forward primer 5′
TGGCTGTTAAAGGCAGTTTGG 3′ and reverse primer 5′ GCACTC-
CATTTTCGTCAAATCTT 3′ with detection of ampliﬁed sequences by a
Taqman probe (5′ TCCAATATCTGGAACAGTTCAAGTGCTCATCT 3′),
which was labelled at the 5′ end with the FAM ﬂuorophore and at the
3′ end with the TAMRA quencher. Primers and probe were purchased
from SigmaGenosys (Pampisford, Cambridgeshire, UK). Reactionswere
carried out in a total volumeof 25 μl in ABI TaqmanMastermix (Applied
Biosystems, Warrington, Cheshire, UK) containing primers and probes
at concentrations of 1.0 and 0.1 μM, respectively. All non-DNA-contain-
ing components were UV irradiated for 15 min prior to reactions being
set up in a sterile environment. Thermocycling parameters were
optimized as 2 min at 50 °C, 15 min at 95 °C followed by 40 cycles of
95 °C (30 s) and60 °C (2 min). Analysis of datawas carriedoutusingABI
software and test samples compared to standards of known viral
content based on picogreen analysis. Standard curveswere prepared for
individual tissue types by spiking serial dilutions of virus into control
tissues and extracting DNA (according to manufacturer's instructions)
for Q-PCR analysis.
Fig. 1. Correlation ofMHES-retargeted virus transduction ofHUVECswith TNF-α-mediated
E-selectin up-regulation. (a, b) E-selectin expression in (a) non-rhTNF-α-activated and
(b) rhTNF-α-activated HUVECs. (c, d) Transduction efﬁciency of MHES-retargeted
polymer coated adenovirus (prepared by direct conjugation) in (c) E-selectin-negative
and (d) E-selectin-positiveHUVECs. Ad, unmodiﬁed adenovirus; pcAd, pHPMA-adenovirus;
IgGpcAd, isotype control-pHPMA-adenovirus; and MHESpcAd, MHES-retargeted-pHPMA-
adenovirus. Results are representative of at least three different experiments. Error bars
are±standarddeviation. P values calculatedusinga one-wayANOVA (analysis of variance).
**Pb0.01, ***Pb0.001.
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The data are expressed as the mean of 3–4 replicates±standard
deviation unless otherwise stated. Signiﬁcance was evaluated using aone-way ANOVA (analysis of variance) with post-hoc analysis using
Tukey's test: ⁎⁎⁎pb0.001, ⁎⁎pb0.01, ⁎pb0.05.
3. Results
3.1. Transduction efﬁciency of pHPMA-adenovirus retargeted via E-selectin
in non-rhTNF-α- versus rhTNF-α-activated HUVECs in vitro
In order to induce an activated phenotype in endothelial cells that
would mimic the tumour microenvironment and induce E-selectin up-
regulation,HUVECswere treatedwith rhTNF-α (100 ng/ml) for 4 h [12].
The E-selectin expression level in non-treated versus rhTNF-α-treated
cells was determined by ﬂow cytometry. Non-rhTNF-α-activated
HUVECs do not express E-selectin (Fig. 1a) and were barely transduced
by adenoviruses bearing mouse anti-human E-selectin monoclonal
antibodies (MHESpcAdluc) (Fig. 1c). In contrast a 4-h rhTNF-α
treatment up-regulated E-selectin expression (Fig. 1b), resulting in a
signiﬁcant increase in transduction efﬁciency of the E-selectin-targeted
virus (Fig. 1d). MHESpcAdluc demonstrated 34.8-fold higher transgene
levels compared with polymer coated virus and 18.3-fold higher
infection efﬁciency in receptor-positive compared with receptor-
negative cells. Retargeting virus with an isotype control antibody
(IgGpcAdluc), did not restore viral infection in E-selectin-expressing
cells, (Fig. 1d).
Although MHESpcAdluc showed encouraging luciferase activity, the
use of antibodies for direct conjugation to polymer coated viruses occurs
randomly and is subject to variability between different antibodies
depending on their availability of reactive amino groups (Fig. 2a). Hence,
alternative strategies of ligand-conjugation were considered using
Streptococcal protein G as a platform system for targeting receptors of
interest.
3.2. Streptococcal protein G as a platform system for targeting E-selectin
in vitro
In order to enable orientated linkage of Fc-bearing ligands
including MHES monoclonal antibody, protein G was directly
incorporated onto polymer coated virus (StrepGpcAdluc). The
amount of protein G molecules associated with each virus was
determined by dot blot analysis using a protein G standard curve
(Supplementary Fig. 1). On average each virus particle (determined
by pico green analysis) was associated with 169 attograms of protein
G equivalent to 4700 (+/− 815) molecules of protein G. However by
Western blot analysis we could not rule out the possibility that free
protein G remained associated with the virus even after puriﬁcation
by caesium chloride centrifugation (data not shown); suggesting that
this value is an over-estimate of the number of molecules covalently
attached to the polymer. MHES or IgG antibodies, were then
conjugated to StrepGpcAdluc to generate retargeted virus (MHES-
StrepGpcAdluc, IgG-StrepGpcAdluc). As shown in Fig. 2b (black bars),
StrepGpcAdluc generated minimal non-speciﬁc binding while MHES-
StrepGpcAdluc demonstrated efﬁcient endothelial transduction com-
pared with both Adluc and IgG-StrepGpcAdluc. Blocking CAR knocks
down Adluc infection by 4-fold with no effect on the transduction
efﬁciency of MHES-StrepGpcAdluc (Fig. 2b dark grey bars). Further-
more, infection in the presence of competing free MHES monoclonal
antibody (intended to outcompete binding for E-selectin), resulted in
almost 5-fold less transgene expression in HUVECs transduced with
the MHES-retargeted virus; while Adluc, protein G-modiﬁed and IgG-
control viruses remained unaffected by E-selectin blockade. Free IgG
monoclonal antibody also interfered with MHES-retargeted virus
transduction, resulting in 2.9-fold decrease in infection efﬁciency. This
observation suggests some possible limitations in retargeting using
the protein G-platform system and highlights its potential suscepti-
bility to competition from plasma IgGs.
Fig. 2. Streptococcal protein G as a platform system for targeting E-selectin in vitro.
(a) Diagram illustrating concept of retargeting pcAdluc by linking antibodies via protein
G. Polymer coated virus shown in grey. (b) Retargeting protein G-pHPMA-coated adenovirus
viaE-selectin in rhTNF-α-activatedHUVECs.Ad,unmodiﬁedadenovirus;StrepGpcAd,protein
G-pHPMA-adenovirus; IgG-StrepGpcAd, isotype control-protein G-pHPMA-adenovirus; and
MHES-StrepGpcAd, MHES-retargeted-protein G-pHPMA-adenovirus. Results are represen-
tative of three different experiments. Error bars are±standard deviation. P values calculated
using a one-way ANOVA (analysis of variance). *Pb0.05, **Pb0.01, and ***Pb0.001.
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vein cord model
Because of the lack of cross species reactivity between mice and
humans, the infection efﬁciency of the MHES-retargeted virus could
not be tested in vivo in tumour-bearingmice. Instead, the ability of the
virus to infect and transduce polarised human endothelial cells
(within their correct architectural organisation), was tested ex vivo in
a human umbilical vein cord model (Fig. 3a).
Immunohistochemical staining of umbilical cord sections infected
(in the absence of activation by rhTNF-α) with Adluc, revealed traces
of luciferase transgene expression (observed as green signals in
Fig. 3b) which appeared to co-localise with CD31-stained endothelial
cells (stained in red). In contrast infection with the MHES-retargeted
virus gave very little transgene expression (Fig. 3b). However, when
the cord was treated with rhTNF-α for 4 h prior to infection, a marked
increase in transgene expression from MHES-StrepGpcAdluc was
observed, likely reﬂecting up-regulation of E-selectin expression on
the surface of polarised endothelial cells allowing their transduction.
In contrast, luciferase transgene expression from the unmodiﬁed virus
was abrogated after rhTNF-α treatment of the cord (Fig. 3b).
3.4. Protein G as a platform system for targeting viruses using alternative
ligands in vitro
One advantage of the protein G targeting system is ﬂexibility in ligand
choice allowing incorporation of any ligand bearing an appropriate Fc
region. The ability of this system to target endothelial selectins, mostly E-selectinbut alsoP-selectinexpressedonendothelial cells,was testedusing
two alternative ligands. In order to target StrepGpcAdluc to murine
vasculature associated with human tumour xenografts, a rat anti-mouse
E-selectin IgG2a monoclonal antibody (RMES mAb) and a chimeric P-
selectin Glycoprotein Ligand-1 (PSGL-1)-Fc fusion protein were tested as
alternative targeting ligands. The incorporation of RMES mAb resulted in
an enhancement in the transduction efﬁciency of murine bEnd3 cells,
usually very poorly transduced by adenovirus, with an optimal ligand
concentration of 1 μg/ml (Fig. 4a). At this concentration RMES-StrepGp-
cAdluc generated 10-fold higher transgene expression compared to the
non-modiﬁed virus. Retargeting the virus with PSGL-1-Fc also resulted in
improved transduction of murine endothelium, in a ligand concentration
dependentmanner,which at optimal concentration (10 μg/ml) generated
18.4-fold greater endothelial transduction compared with unmodiﬁed
virus and 35.4-fold higher transgene expression than StrepGpcAdluc
(Fig. 4b). Based on performance criteria in vitro, the PSGL-1-Fc-targeting
system was taken forward for study in vivo.
3.5. Targeting pHPMA-adenovirus to selectin-expressing endothelium in vivo
Intravenous injections of viruses in tumour-bearing mice revealed
marked differences in blood circulation proﬁles between Adluc and the
retargeted virus (PSGL-1-Fc-StrepGpcAdluc). While Adluc experienced a
rapid clearance from the bloodstream, measured by real time (quantita-
tive) PCR, falling to 1% of the input dose remaining in the plasma after
20 min, compatible with the ﬁrst pass hepatic clearance mechanism; the
PSGL-1-retargeted virus showed extended circulation kinetics, with
approximately 17.1% of the input dose still in the bloodstream after
30 min (Fig. 5a). This is approximately 38 times higher than the
unmodiﬁed virus. This enhanced circulation property is attributed to the
pHPMA polymer used to coat the virus, prolonging its survival in the
bloodstream as previously demonstrated by Green et al. [27]. This
extension in plasma circulation time thus provides a better platform for
efﬁcient targeting of distant tumour sites.
The ability of the PSGL-1-retargeted virus to reach a distant
subcutaneous tumour following systemic administration was subse-
quently investigated in a separate study in which PSGL-1-Fc-StrepGpcAd
was directly compared with non-modiﬁed virus (Adluc) and two control
modiﬁed viruses (StrepGpcAd and IgG1-Fc-StrepGpcAd). Following
intravenous administration of 1×1010 virus particles/mouse, PSGL-1-Fc-
StrepGpcAdluc efﬁciently accumulated in HepG2 human tumour xeno-
grafts implanted subcutaneously into CD1 nudemice,with an overall ratio
of 345.5-, 36- and 43.7-fold higher virus genomic copies compared with
StrepGpcAdluc, Adluc and the IgG1-Fc-StrepG-modiﬁed control virus,
respectively (Fig. 5b).
3.6. Efﬁciency of the PSGL-1-Fc-retargeted virus to infect endothelial cells
in tumour xenografts following systemic administration
The previous ﬁndings have shown that the PSGL-1-retargeted virus
can accumulate efﬁciently into tumours following systemic administra-
tion. However these quantiﬁcation studies do not reveal which cell
population within the tumour tissue has been infected. Since the
retargeted virus was designed to infect endothelial cells, it was important
to assess whether the expressed transgene co-localised with the
endothelial cells of HepG2 tumour xenografts. Tumour sections from
PSGL-1-Fc-retargeted virus and Adluc-treated mice were double-stained
for CD31 (an endothelial marker) and ﬁreﬂy luciferase (the expressed
transgene). Different patterns of staining were observed in tumours from
animals treatedwith the PSGL-1-retargetedvirus (Fig. 6a-c, j–l) compared
with those treated with the non-modiﬁed virus (Fig. 6d–f, m–o). While a
more endothelial-localised luciferase staining (shown in green) was
observed in PSGL-1-Fc-StrepGpcAdluc-infected tumour sections, a dis-
perse staining in close proximity but not within blood vessels was seen in
Adluc-infected tumour sections. A co-localisation of luciferase expression
(green signal) with CD31-positive tumour-associated endothelium (red
Fig. 3. Transduction efﬁciency of MHES-StrepGpcAdluc in a human umbilical vein cord
model ex vivo. (a) Diagram illustrating the handling procedure of human umbilical vein
infectionwithAdluc andMHES-StrepGpcAdluc exvivo. (b) Immunohistochemistry staining
of human umbilical vein sections treatedwith PBS or rhTNF-α and infectedwith Adluc and
MHES-StrepGpcAdluc. CD31 in red; Fireﬂy luciferase in green; CD31/Fireﬂy luciferase co-
localisation is seen where the merged ﬂuorescence is yellow. Scale bars represent 20 μm.
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merging individual luciferase-positive and CD31-positive pictures. Tu-
mour sections frommice treatedwith PBSwere used as a negative control
to account for any unspeciﬁc binding from the antibody used to stain
luciferase in tumour samples transduced by Adluc and the retargeted
virus. The results clearly show that PSGL-1-Fc-StrepGpcAdluc and Adluc
are not infecting the same cell populations within the tumour tissue and
that the retargeted virus is indeed speciﬁcally infecting endothelial cells.
4. Discussion
Adenoviral vectors do not generally perform well following intrave-
nous delivery because they are rapidly inactivated and cleared by theinnate and adaptive immune system. Our group has previously shown
that stealthing adenovirus particles withmultivalent reactive copolymers
based on poly-[N-(2-hydroxypropyl)methacrylamide] (pHPMA) protects
virus surface epitopes from interaction with the environment [23] and
gives an impressive extension in plasma circulation kinetics following
intravenous delivery [27]. The tropism-ablated polymer coated virus can
then be retargeted with various molecules including growth factors
[23,28–30],monoclonal antibodies [24] andpeptides [22] to infect cells via
endosome-internalising receptors of interest.
Endothelial selectins represent an attractive target, given their
physiological roles in binding circulating blood cells under shear blood
ﬂow conditions, and their pattern of selective expression at sites of
inﬂammation such as in tumours. In vitro a 4-h activation of HUVECswith
rhTNF-α is sufﬁcient to induce a substantial (8-fold increase in GMean
value) up-regulation in the E-selectin level. This enables ligand-speciﬁc
transductionof E-selectin-expressing endothelial cells, following infection
with the MHES-retargeted virus.
While the linkage of E-selectin antibodies to the surface of adenovirus
has previously been reported for targeting activated endothelial cells,
previous strategies have employed PEG to mediate attachment [12].
Ogawara et al. used bifunctional PEG containing N-hydroxysuccinimide
ester (NHS) and vinyl sulfone (VS) groups at each end of themolecule, to
react (via NHS esters) with primary amino groups on the surface of the
virus preventing ﬁbre/CAR attachment, while remaining VS groups were
available to bind targeting antibodies. The use of multivalent pHPMA
based copolymers, which are able to bind to the virus surface bymultiple
linkages [23], provides not only a platform to prevent CAR/intergrin
mediated uptake and attachment of targeting antibodies but can also
improve shielding against components within the blood [31]. Avoidance
of neutralising antibodies, coagulation factors and complement is a
prerequisite for systemic delivery routes accessing tumours via the
vasculature.
The use of antibodies for direct conjugation to polymer coated viruses,
remains however problematic. This strategy is subject to variability
between different antibody molecules depending on their content of
reactive amino groups, leading to a mixture of orientations sometimes
with exposed Fc regions, which might resemble immune complexes.
Hence, strategies to minimise Fc exposure were deemed important and
alternative approaches of orientated ligand-conjugation were investigat-
ed based on adaptor proteins.
Following the reported success of using S. aureus protein A to correctly
orientate antibody based ligands [25], we tested the use of protein A to
attach MHES to polymer coated Ad. Transduction of TNF-α stimulated
HUVECs resulted in a 30-fold increase in transgene expression from
MHES-StaphApcAdluc compared with Adluc (data not shown). However
the use of an isotype control antibody also substantially increased
transduction of the endothelial cells compared to the unmodiﬁed virus
(data not shown). Even without addition of targeting antibody, the
presence of the S. aureus protein A increased transgene expression 4-fold
over Adluc (data not shown). Given the high degree of non-speciﬁc
binding engendered by protein A in this conﬁguration, attention was
focussedonanalternativemechanismof attachmentnamely Streptococcal
aureus protein G.
Using in vitro studieswehavevalidated the concept of usingproteinG-
modiﬁed virus to allow spontaneous binding of monoclonal antibodies
against E-selectin, leading to receptor-mediated infection. Importantly
this method unlike protein A did not result in substantial non-speciﬁc
binding and transduction of target cells (Fig. 1c and d, compare pcAdluc
and IgGpcAdluc). This systemcould clearly be easily adapted for linkage of
any Fc-containing retargeting ligand. In this manner we believe that
protein G modiﬁcation will provide a useful tool to screen candidate cell
surface receptors for targeting, by displaying correctly oriented antibodies
on the surface of the polymer coated virus.
In an ex vivomodel of human umbilical vein cord transduced with
Adluc or MHES-StrepGpcAdluc following treatment with PBS or
rhTNF-α, the ability of the retargeted virus to infect a polarised layer
Fig. 4. Retargeting protein G-pHPMA-coated adenovirus using alternative Fc-bearing
ligands targeting murine endothelia. (a) Transduction of murine bEnd3 cells using
StrepGpcAdluc retargeted via E-selectin with a rat anti-mouse E-selectin IgG2a
monoclonal antibody (RMES mAb). (b) Transduction of murine bEnd3 cells using
StrepGpcAdluc retargeted via P-selectin with a chimeric P-selectin Glycoprotein Ligand-1
(PSGL-1)-Fc fusion protein. In each case prior to infection cells were treated with
recombinant murine-TNF-α (rmTNF-α, 120 ng/ml) for 5 h at 37 °C. Ad, unmodiﬁed
adenovirus; pcAd, pHPMA-adenovirus; StrepGpcAd, protein G-pHPMA-adenovirus;
RMES-StrepGpcAd, RMES retargeted-protein G-pHPMA-adenovirus; and PSGL-1-Fc-
StrepGpcAd, PSGL-1 retargeted-protein G-pHPMA-adenovirus. Results are representative
of at least three different experiments. Error bars are±standard deviation. P values were
calculated using a one-way ANOVA (analysis of variance). *Pb0.05, **Pb0.01.
Fig. 5. Pharmacokinetics of PSGL-1-Fc retargeted virus. (a) Blood circulation proﬁle of
PSGL-1-Fc-StrepGpcAd (squares) and Adluc (diamonds) in vivo following intravenous
administration of 1e10 virus particles. (b) Number of virus genomic copies recovered
from HepG2 xenograft tumours following administration of Adluc, StrepGpcAdluc,
IgG1-StrepGpcAdluc or PSGL-1-Fc-StrepGpcAdluc. P values were calculated using a
one-way ANOVA (analysis of variance). *Pb0.05.
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cells with rhTNF-α, the non-modiﬁed (Ad) virus failed to show
transduction, while the E-selectin-targeted virus gave a high
frequency of transduced cells. This is in agreement with rhTNF-α-
induced over expression of E-selectin in vitro, ex vivo and in vivo [32–
34]. The inability of unmodiﬁed Ad to infect endothelial cells in the
presence of rhTNF-αmight reﬂect down-regulation of viral receptors.
While rhTNF-α increases the expression of E-selectin, P-selectin,
ICAM-1, and vascular cell adhesion molecule (VCAM-1) on endothe-
lial cells [35], it can also change the distribution of some surface
proteins away from sites of inter-endothelial cell contact [36]. It can
also down-regulate cell surface expression of some proteins such as:
platelet endothelial cell adhesion molecule-1 (PECAM-1) [37,38] as
well as αvβ3 integrin [39] and CAR [40]; the pivotal receptors for Ad
binding and internalisation [41,42].
This systemwas also tested in vivo, where a protein G-modiﬁed virus
retargeted with a chimeric P-selectin Glycoprotein Ligand-1 (PSGL-1)-Fc
fusion proteinwas injected i.v. to target tumour-associated vasculature in
tumour-bearing mice. The retargeted virus showed endothelial celltransduction and a better tumour accumulation with an average of
36 fold higher virus uptake compared with unmodiﬁed virus.
The ability of freeantibodies to outcompete the retargeting ligand for
the protein G-modiﬁed virus (Fig. 2b) must be taken into consideration
in the design of extended duration experiments, although it appears to
have only limited consequences for in vivo targeting studieswhere virus
kinetics are generally short.
These ﬁndings highlight the possibility to deliver genes selectively
to tumour-associated vasculature providing an alternative to direct
tumour cell targeting. Endothelial targeting bypasses the need for
extravasation which can limit targeting delivery.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.jconrel.2010.10.011.Conﬂict of interest
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Fig. 6. Targeting endothelial cells in human tumour xenografts by systemic vector
administration. Cryostat sections (10 μm) of HepG2 tumour xenografts from mice injected
with Adluc or PSGL-1-Fc-StrepGpcAdluc. Photomicrographs were taken using a confocal
microscope (Nikon Optiphot-2 upright microscope). (a–c) 20× and (j–l) 60× PSGL-1-Fc-
StrepGpcAdluc-infected tumour sections; (d–f) 20× and (m–o) 60× Adluc-infected tumour
sections; (g–i) 20× PBS-treated tumour sections. CD31 in red; Fireﬂy luciferase in green;
CD31/Fireﬂy luciferase co-localisation (orange/yellow).
203H. Bachtarzi et al. / Journal of Controlled Release 150 (2011) 196–203
G
E
N
E
D
E
L
IV
E
R
YReferences
[1] R.M. Hughes, Strategies for cancer gene therapy, J. Surg. Oncol. 85 (1) (2004)
28–35.
[2] M. De Palma, M.A. Venneri, L. Naldini, In vivo targeting of tumor endothelial cells
by systemic delivery of lentiviral vectors, Hum. Gene Ther. 14 (12) (2003)
1193–1206.
[3] A. Tandle, et al., Tumor vasculature-targeted delivery of tumor necrosis factor-
alpha, Cancer 115 (1) (2009) 128–139.
[4] J. Denekamp, Vascular attack as a therapeutic strategy for cancer, Cancer
Metastasis Rev. 9 (3) (1990) 267–282.
[5] A.H. Sprague, R.A. Khalil, Inﬂammatory cytokines in vascular dysfunction and
vascular disease, Biochem. Pharmacol. 78 (6) (2009) 539–552.
[6] H.H. Sedlacek, Pharmacological aspects of targeting cancer gene therapy to
endothelial cells, Crit. Rev. Oncol. Hematol. 37 (3) (2001) 169–215.
[7] E. Ruoslahti, Specialization of tumour vasculature, Nat. Rev. Cancer 2 (2) (2002) 83–90.
[8] L.J. Picker, E.C. Butcher, Physiological and molecular mechanisms of lymphocyte
homing, Annu. Rev. Immunol. 10 (1992) 561–591.
[9] S.R. Barthel, et al., Targeting selectins and selectin ligands in inﬂammation and
cancer, Expert Opin. Ther. Targets 11 (11) (2007) 1473–1491.
[10] V. Bhaskar, et al., E-selectin up-regulation allows for targeted drug delivery in
prostate cancer, Cancer Res. 63 (19) (2003) 6387–6394.
[11] G. Hariri, et al., Radiation-guided P-selectin antibody targeted to lung cancer, Ann.
Biomed. Eng. 36 (5) (2008) 821–830.[12] K. Ogawara, et al., A novel strategy to modify adenovirus tropism and enhance
transgene delivery to activated vascular endothelial cells in vitro and in vivo,
Hum. Gene Ther. 15 (5) (2004) 433–443.
[13] K.R. Zinn, et al., Bioluminescence imaging reveals a signiﬁcant role for
complement in liver transduction following intravenous delivery of adenovirus,
Gene Ther. 11 (19) (2004) 1482–1486.
[14] Z. Xu, et al., Clearance of adenovirus by Kupffer cells is mediated by scavenger
receptors, natural antibodies, and complement, J. Virol. 82 (23) (2008)
11705–11713.
[15] M. Lyons, et al., Adenovirus type 5 interactions with human blood cells may
compromise systemic delivery, Mol. Ther. 14 (1) (2006) 118–128.
[16] D. Stone, et al., Adenovirus–platelet interaction in blood causes virus sequestra-
tion to the reticuloendothelial system of the liver, J. Virol. 81 (9) (2007)
4866–4871.
[17] R.C. Carlisle, et al., Human erythrocytes bind and inactivate type 5 adenovirus by
presenting Coxsackie virus-adenovirus receptor and complement receptor 1,
Blood 113 (9) (2009) 1909–1918.
[18] D.M. Shayakhmetov, et al., Adenovirus binding to blood factors results in liver cell
infection and hepatotoxicity, J. Virol. 79 (12) (2005) 7478–7491.
[19] A.L. Parker, et al., Inﬂuence of coagulation factor zymogens on the infectivity of
adenoviruses pseudotyped with ﬁbers from subgroup D, J. Virol. 81 (7) (2007)
3627–3631.
[20] S. Worgall, et al., Innate immune mechanisms dominate elimination of
adenoviral vectors following in vivo administration, Hum. Gene Ther. 8 (1)
(1997) 37–44.
[21] G. Wolff, et al., Enhancement of in vivo adenovirus-mediated gene transfer and
expression by prior depletion of tissue macrophages in the target organ, J. Virol.
71 (1) (1997) 624–629.
[22] M. Stevenson, et al., Incorporation of a laminin-derived peptide (SIKVAV) on
polymer-modiﬁed adenovirus permits tumor-speciﬁc targeting via alpha6-
integrins, Cancer Gene Ther. 14 (4) (2007) 335–345.
[23] K.D. Fisher, et al., Polymer-coated adenovirus permits efﬁcient retargeting and
evades neutralising antibodies, Gene Ther. 8 (5) (2001) 341–348.
[24] J. Morrison, et al., Cetuximab retargeting of adenovirus via the epidermal growth
factor receptor for treatment of intraperitoneal ovarian cancer, Hum. Gene Ther.
20 (3) (2009) 239–251.
[25] N. Korokhov, et al., Targeting of adenovirus via genetic modiﬁcation of the viral
capsid combined with a protein bridge, J. Virol. 77 (24) (2003) 12931–12940.
[26] P. Murakami, M.T. McCaman, Quantitation of adenovirus DNA and virus particles
with the PicoGreen ﬂuorescent Dye, Anal. Biochem. 274 (2) (1999) 283–288.
[27] N.K. Green, et al., Extended plasma circulation time and decreased toxicity of
polymer-coated adenovirus, Gene Ther. 11 (16) (2004) 1256–1263.
[28] K.D. Fisher, et al., Passive tumour targeting of polymer-coated adenovirus for
cancer gene therapy, J. Drug Target. 15 (7–8) (2007) 546–551.
[29] N.K. Green, et al., Retargeting polymer-coated adenovirus to the FGF receptor
allows productive infection and mediates efﬁcacy in a peritoneal model of human
ovarian cancer, J. Gene Med. 10 (3) (2008) 280–289.
[30] J. Morrison, et al., Virotherapy of ovarian cancer with polymer-cloaked adenovirus
retargeted to the epidermal growth factor receptor, Mol. Ther. 16 (2) (2008)
244–251.
[31] D. Oupicky, et al., Importance of lateral and steric stabilization of polyelectrolyte
gene delivery vectors for extended systemic circulation, Mol. Ther. 5 (4) (2002)
463–472.
[32] S.D. Rosen, Cell surface lectins in the immune system, Semin. Immunol. 5 (4)
(1993) 237–247.
[33] S. Theoharis, et al., Targeting gene delivery to activated vascular endothelium
using anti E/P-selectin antibody linked to PAMAM dendrimers, J. Immunol.
Methods 343 (2) (2009) 79–90.
[34] H.W. Kang, et al., Targeted imaging of human endothelial-speciﬁc marker in a
model of adoptive cell transfer, Lab. Invest. 86 (6) (2006) 599–609.
[35] M.P. Bevilacqua, et al., Identiﬁcation of an inducible endothelial-leukocyte
adhesion molecule, Proc. Natl Acad. Sci. USA 84 (24) (1987) 9238–9242.
[36] L.H. Romer, et al., IFN-gamma and TNF-alpha induce redistribution of PECAM-1
(CD31) on human endothelial cells, J. Immunol. 154 (12) (1995) 6582–6592.
[37] Y. Rival, et al., Inhibition of platelet endothelial cell adhesionmolecule-1 synthesis
and leukocyte transmigration in endothelial cells by the combined action of TNF-
alpha and IFN-gamma, J. Immunol. 157 (3) (1996) 1233–1241.
[38] R.J. Stewart, T.S. Kashour, P.A. Marsden, Vascular endothelial platelet endothelial
adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-
gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic
acid transcripts in bovine endothelial cells, J. Immunol. 156 (3) (1996)
1221–1228.
[39] P. Deﬁlippi, et al., Tumor necrosis factor alpha and interferon gamma modulate
the expression of the vitronectin receptor (integrin beta 3) in human endothelial
cells, J. Biol. Chem. 266 (12) (1991) 7638–7645.
[40] T. Vincent, et al., Cytokine-mediated downregulation of coxsackievirus-adenovirus
receptor in endothelial cells, J. Virol. 78 (15) (2004) 8047–8058.
[41] J. Howitt, C.W. Anderson, P. Freimuth, Adenovirus interaction with its cellular
receptor CAR, Curr. Top. Microbiol. Immunol. 272 (2003) 331–364.
[42] T.J. Wickham, et al., Integrins alpha v beta 3 and alpha v beta 5 promote
adenovirus internalization but not virus attachment, Cell 73 (2) (1993) 309–319.
